About: Drug-induced ‘Torsade de Pointes’ in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Drug-induced ‘Torsade de Pointes’ in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Drug-induced ‘Torsade de Pointes’ in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report
Creator	Camm, Christian Kapel, Gijs Khan, Habib Semedo, Edimir van Dessel, Pascal van Opstal, Jurren
Source	PMC
abstract	BACKGROUND: Early studies have led to the repositioning of a subgroup of antimalarial agents (e.g. chloroquine and hydroxychloroquine) as antiviral treatment in coronavirus disease 2019 (COVID-19) patients. These drugs are now being prescribed based on small non-controlled studies, but larger controlled studies have yet to demonstrate the positive effect of these drugs. In addition, these drugs are also known for their QT interval-prolonging effect associated with significant morbidity and mortality. CASE SUMMARY: We present a case of a 66-year-old female admitted to the intensive care unit with respiratory failure due to COVID-19. She was treated with chloroquine (QTc interval at baseline was 429 ms). Despite cessation of chloroquine, but after the start of erythromycin, she developed severe QTc interval prolongation (QTc interval 550 ms) and ‘Torsade de Pointes’. Two weeks after cessation of all QTc interval-prolonging drugs, the QTc interval was restored. DISCUSSION: The elimination half-life of chloroquine ranges from days up to weeks. Even after discontinuation of chloroquine, ECG monitoring in COVID-19 patients is warranted. We recommend observation of the QT interval after cessation of chloroquine in cases where other potentially QT interval-prolonging drugs are introduced.
has issue date	2020-07-21(xsd:dateTime)
bibo:doi	10.1093/ehjcr/ytaa218
has license	cc-by-nc
schema:url	https://doi.org/10.1093/ehjcr/ytaa218
resource representing a document's title	Drug-induced ‘Torsade de Pointes’ in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report
has PubMed Central identifier	PMC7454487
schema:publication	Eur Heart J Case Rep
resource representing a document's body	covid:PMC7454487#body_text
is schema:about of	named entity 'case report' named entity 'Drug-induced' named entity 'chloroquine' named entity 'COVID-19' named entity 'electrolytes' named entity 'heart disease' named entity 'QT interval prolongation' named entity 'hypercholesterolaemia' named entity 'significant effect' named entity 'C-reactive protein' named entity 'Bradycardia' named entity 'risk factors' named entity 'antimalarial drugs' named entity 'gliclazide' named entity 'mechanical ventilation' named entity 'Netherlands' named entity 'risk factors' named entity 'heart rate' named entity 'COVID' named entity 'systemic lupus erythematosus' named entity 'EADs' named entity 'chloroquine' named entity 'coronavirus disease 2019' named entity 'ischaemia' named entity 'COVID-19.' named entity 'impaired renal function' named entity 'loading dose' named entity 'coronavirus' named entity 'heart rhythm' named entity 'erythromycin' named entity 'TdP' named entity 'cardiac catheterization' named entity 'type 2 diabetes mellitus' named entity 'general practitioner' named entity 'half-life' named entity 'drug-induced' named entity 'blood pressure' named entity 'QTc prolongation' named entity 'randomized controlled trials' named entity 'metabolically active' named entity 'congenital' named entity 'coronary artery disease' named entity 'Wuhan' named entity 'crackles' named entity 'antimalarials' named entity 'Transthoracic echocardiogram' named entity 'chloroquine' named entity 'electrolyte disturbances' named entity 'electrophysiology' named entity 'Chloroquine' named entity 'Pulmonary examination' named entity 'RT-PCR' named entity 'renal function' named entity 'half-life' named entity 'ciprofloxacin' named entity 'reverse transcription-polymerase chain reaction' named entity 'intravenous' named entity 'COVID' named entity 'creatinine levels' named entity 'chloroquine' named entity 'ventricular ectopy' named entity 'tachypnoea' named entity 'medical history' named entity 'repolarization' named entity 'life-threatening' named entity 'ECG monitoring' named entity 'phosphate' named entity 'μmol/L' named entity 'sodium' named entity 'hydroxychloroquine' named entity 'Ceftriaxone' named entity 'IKr' named entity 'Torsade de Pointes' named entity 'TdP' named entity 'half-life' named entity 'adverse effects' named entity 'SARS-CoV-2' named entity 'metabolic' named entity 'QTc interval prolongation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software